Molecular markers and bladder carcinoma: Schistosomal and non-schistosomal.

[1]  M. Swellam,et al.  Expression of HYAL1 and survivin RNA as diagnostic molecular markers for bladder cancer. , 2010, The Journal of urology.

[2]  R. Hafidh,et al.  Tumor markers of bladder cancer: the schistosomal bladder tumors versus non-schistosomal bladder tumors , 2009, Journal of experimental & clinical cancer research : CR.

[3]  M. Swellam,et al.  Detection of telomerase in urine by 3 methods: evaluation of diagnostic accuracy for bladder cancer. , 2007, The Journal of urology.

[4]  S. Goodison,et al.  Immunohistochemical detection of hTERT in urothelial lesions: a potential adjunct to urine cytology , 2006, CytoJournal.

[5]  M. Hassouna,et al.  Telomerase activity, cytokeratin 20 and cytokeratin 19 in urine cells of bladder cancer patients. , 2006, Journal of the Egyptian National Cancer Institute.

[6]  Dafydd G. Thomas,et al.  hTERT expression in melanocytic lesions: an immunohistochemical study on paraffin‐embedded tissue , 2005, Journal of cutaneous pathology.

[7]  Na Mi,et al.  Comparative study of NMP-22, telomerase, and BTA in the detection of bladder cancer. , 2005 .

[8]  E. Mylona,et al.  Nuclear hTERT immunohistochemical expression is associated with survival of patients with urothelial bladder cancer. , 2005, Anticancer research.

[9]  P. Ekman,et al.  Differential Expression of Full-length Telomerase Reverse Transcriptase mRNA and Telomerase Activity between Normal and Malignant Renal Tissues , 2005, Clinical Cancer Research.

[10]  S. Artandi,et al.  Pathways connecting telomeres and p53 in senescence, apoptosis, and cancer. , 2005, Biochemical and biophysical research communications.

[11]  Jiunn-Liang Chen,et al.  Functional analysis of the pseudoknot structure in human telomerase RNA. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[12]  M. Matuszewski,et al.  Telomerase activity in urine sediments as a tool for noninvasive detection of bladder cancer. , 2005, Cancer letters.

[13]  J. Shay.  Meeting report: the role of telomeres and telomerase in cancer. , 2005, Cancer research.

[14]  I. Sesterhenn,et al.  World health organization classifications of tumours. pathology and genetics of tumours of the urinary system and male genital organs , 2005 .

[15]  J. Cheville,et al.  Prognostic value of p53 and MIB‐1 in transitional cell carcinoma of the urinary bladder with regional lymph node involvement , 2004, Cancer.

[16]  A. Scovassi,et al.  Telomeres, telomerase, and apoptosis. , 2004, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[17]  Kazuhiro Yoshida,et al.  [Telomerase activity in gastrointestinal, bladder and breast carcinomas and their clinical applications]. , 2004, Nihon rinsho. Japanese journal of clinical medicine.

[18]  F. Bosman,et al.  Immunohistochemical localization of hTERT protein in human tissues , 2004, Histochemistry and Cell Biology.

[19]  C. Cohen,et al.  Muscle invasive schistosomal squamous cell carcinoma of the urinary bladder: frequency and prognostic significance of p53, BCL-2, HER2/neu, and proliferation (MIB-1). , 2004, Human pathology.

[20]  Y. Soini,et al.  p53 and c-erbB-2 expression in schistosomal urinary bladder carcinomas and schistosomal cystitis with premalignant lesions , 2004, Virchows Archiv.

[21]  B. Stillman,et al.  Biochemical Characterization of DNA Damage Checkpoint Complexes: Clamp Loader and Clamp Complexes with Specificity for 5′ Recessed DNA , 2003, PLoS biology.

[22]  H. Kim,et al.  The expression of bcl-2 and bcl-6 protein in normal and malignant transitional epithelium , 2003, Urological Research.

[23]  R. Reddel,et al.  Alternative lengthening of telomeres: dangerous road less travelled , 2003, The Lancet.

[24]  K. Iczkowski,et al.  Telomerase reverse transcriptase subunit immunoreactivity , 2002, Cancer.

[25]  E. Ioachim,et al.  Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer. , 2002, Anticancer research.

[26]  Dah-Shyong Yu,et al.  The Expression of Oncoproteins in Transitional Cell Carcinoma: Its Correlation with Pathological Behavior, Cell Cycle and Drug Resistance , 2002, Urologia Internationalis.

[27]  T. Esen,et al.  Impact of p53 and Ki‐67 in predicting recurrence and progression of superficial (pTa and pT1) urothelial cell carcinomas of urinary bladder , 2002, Pathology international.

[28]  H. Wolf,et al.  Prognostic Value of p53, p21/WAF1, Bcl-2, Bax, Bak and Ki-67 Immunoreactivity in pT1 G3 Urothelial Bladder Carcinomas , 2001, Tumor Biology.

[29]  H. Khaled,et al.  Telomerase activity in bilharzial bladder cancer. Prognostic implications. , 2001, Urologic oncology.

[30]  L. Klotz,et al.  p53 nuclear accumulation is not associated with decreased disease-free survival in patients with node positive transitional cell carcinoma of the bladder. , 2000, The Journal of urology.

[31]  L. Sobin,et al.  World Health Organization classification of tumors , 2000, Cancer.

[32]  Y. H. Lee,et al.  The role of bcl-2, p53, and ki-67 index in predicting tumor recurrence for low grade superficial transitional cell bladder carcinoma. , 2000, The Journal of urology.

[33]  S. Goodison,et al.  Role of telomerase in cell senescence and oncogenesis. , 2000, Annual review of medicine.

[34]  D. Neal,et al.  Alterations of TP53 in microdissected transitional cell carcinoma of the human urinary bladder: high frequency of TP53 accumulation in the absence of detected mutations is associated with poor prognosis. , 1998, British Journal of Cancer.

[35]  S. C. Yang,et al.  Telomerase: a potential marker of bladder transitional cell carcinoma in bladder washes. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  M. Dimopoulos,et al.  The prevalence of bcl-2, p53, and Ki-67 immunoreactivity in transitional cell bladder carcinomas and their clinicopathologic correlates. , 1998, Human pathology.

[37]  T. Sugino,et al.  Telomerase activity and its inhibition in benign and malignant breast lesions , 1997, The Journal of pathology.

[38]  C. Cordon-Cardo,et al.  Alterations affecting the p53 control pathway in bilharzial-related bladder cancer. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[39]  Kazuhiro Yoshida,et al.  Telomerase activity in bladder carcinoma and its implication for noninvasive diagnosis by detection of exfoliated cancer cells in urine , 1997, Cancer.

[40]  G. Stamp,et al.  Expression of bcl-2 and p53 oncoproteins in schistosomiasis-associated transitional and squamous cell carcinoma of urinary bladder. , 1997, British journal of urology.

[41]  M. Giacca,et al.  Detection of c-erbB-2 amplification in transitional cell bladder carcinoma using competitive PCR technique. , 1996, The Journal of urology.

[42]  S. Hohaus,et al.  Telomerase activity in human laryngeal squamous cell carcinomas. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[43]  A. Nouri,et al.  The relevance of p53 mutation in urological malignancies: possible clinical implications for bladder cancer. , 1996, British journal of urology.

[44]  L. Howell,et al.  Relationship of p53 and bcl-2 to prognosis in muscle-invasive transitional cell carcinoma of the bladder. , 1996, The Journal of urology.

[45]  J. Shay,et al.  Telomerase activity in preneoplastic and neoplastic gastric and colorectal lesions. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[46]  J. Shay,et al.  Telomerase activity in gastric cancer. , 1995, Cancer research.

[47]  M. Stratton,et al.  Mutations in the p53 gene in schistosomal bladder cancer: a study of 92 tumours from Egyptian patients and a comparison between mutational spectra from schistosomal and non-schistosomal urothelial tumours. , 1995, Carcinogenesis.

[48]  C B Harley,et al.  Specific association of human telomerase activity with immortal cells and cancer. , 1994, Science.

[49]  M. Rosin,et al.  Inflammation, chromosomal instability, and cancer: the schistosomiasis model. , 1994, Cancer research.

[50]  R. Cote,et al.  Two molecular pathways to transitional cell carcinoma of the bladder. , 1994, Cancer research.

[51]  Y. Soini,et al.  the urinary bladder correlates with disease progression , 2022 .

[52]  P. Hall,et al.  Detection of the Ki‐67 antigen in fixed and wax‐embedded sections with the monoclonal antibody MIB1 , 1993, Histopathology.

[53]  C. Cordon-Cardo,et al.  Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. , 1993, Journal of the National Cancer Institute.

[54]  T. Bauer,et al.  Ki‐67‐determined growth fraction versus standard staging and grading parameters in colorectal carcinoma: A multivariate analysis , 1992, Cancer.

[55]  T. Mikkelsen,et al.  Clonal expansion of p53 mutant cells is associated with brain tumour progression , 1992, Nature.

[56]  T. Kurita,et al.  Cell proliferation of human bladder tumors determined by BrdUrd and Ki-67 immunostaining. , 1991, The Journal of urology.

[57]  C B Harley,et al.  Telomere loss: mitotic clock or genetic time bomb? , 1991, Mutation research.

[58]  K. Tanaka,et al.  The incidence of squamous and transitional cell carcinomas of the urinary bladder in northern Tanzania in areas of high and low levels of endemic Schistosoma haematobium infection. , 1986, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[59]  M. H. Hussein,et al.  The impact of schistosomiasis on the pathology of bladder carcinoma , 1981, Cancer.

[60]  L. Broström.  The combined effect of interferon and methotrexate on human osteosarcoma and lymphoma cell lines. , 1980, Cancer letters.

[61]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.